Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Discharge Readmission Analysis and Management in Sepsis (DReAMS-2): Augmenting Readmission Risk Models With Smartphone PPG Signals and Deep Learning, an Adaptive Platform

NCT06099756 is registered in ClinicalTrials.gov with Measure Labs, Inc. as lead sponsor.

NCT NCT06099756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06099756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Discharge Readmission Analysis and Management in Sepsis (DReAMS-2): Augmenting Readmission Risk Models With Smartphone PPG Signals and Deep Learning, an Adaptive Platform
Lead sponsor
Measure Labs, Inc.
Phase
Observational
Overall status
Unknown status
Start date
October 26, 2023
Completion date
October 31, 2024
Enrollment
2,000 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis